# Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma

> **NCT01612286** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** endostatin

## Key facts

- **NCT ID:** NCT01612286
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-05
- **Primary completion:** 2013-12
- **Final completion:** 2014-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2014-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01612286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01612286, "Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01612286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*